GLP-1 receptor agonists have expanded from diabetes drugs into potential multi-organ therapeutics, with proven heart and kidney benefits and emerging evidence for liver, brain, lung, cancer, and other applications.
8+ emerging indicationsBeyond approved cardiovascular and renal benefits, GLP-1 receptor agonists show early promise for liver disease, sleep apnea, neurodegeneration, cancer, and more
What the researchers found
GLP-1 receptor agonists have expanded far beyond their original diabetes/obesity indications. The review identifies four key molecular mechanisms underlying their multi-organ effects: immune/inflammatory pathway modulation, autophagy and pyroptosis regulation, endoplasmic reticulum stress alleviation, and gut microbiome interaction.
Clinical evidence now supports cardiovascular and renal protection (with regulatory approvals). Emerging data suggests potential benefits in liver disease, obstructive sleep apnea, chronic respiratory disorders, neurodegenerative diseases, psychiatric conditions, reproductive dysfunction, obesity-associated cancers, and sepsis — though these applications remain investigational.
Why it matters
GLP-1 receptor agonists are arguably the most important peptide drug class of this era, and their therapeutic reach keeps expanding. This review maps the transformation from a diabetes medication to a potential treatment for conditions across virtually every organ system. Understanding the four underlying molecular mechanisms explains why a single peptide can have such wide-ranging effects and guides which new indications are most promising for clinical development.
The numbers in context
4 key mechanisms identified · Cardiovascular + renal protection approved · 8+ emerging indications · Multiple organ systems affected · Immune, autophagy, ER stress, microbiome pathways
How the study worked
Comprehensive narrative review synthesizing evidence from preclinical mechanistic studies and clinical trials on GLP-1RA effects across multiple organ systems. The review integrates molecular mechanism data with clinical outcome evidence to build a framework for understanding GLP-1RA multi-organ potential.
Who was studied
Review covering clinical and preclinical data across multiple patient populations — diabetes, obesity, cardiovascular disease, kidney disease, liver disease, respiratory, neurological, psychiatric, reproductive, and cancer patients
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. Most of the expanded indications beyond cardiovascular and renal protection are based on early or preclinical data. The review does not critically evaluate the strength of evidence for each new indication. Publication bias may favor positive findings. The question of whether GLP-1RA benefits in non-metabolic diseases are direct drug effects or secondary to weight loss and metabolic improvement is not always clearly addressed.
How to read the evidence
Narrative review synthesizing evidence of varying quality — from established RCT data (cardiovascular, renal) to early clinical signals and preclinical findings (neurodegeneration, cancer). The strength of evidence varies dramatically across the different indications discussed.
When this study was published
Published in 2025, this review captures the current frontier of GLP-1 RA research as these peptide drugs rapidly expand into new therapeutic territories.
The bigger picture
The GLP-1 RA story is one of the most remarkable in modern pharmacology — a peptide originally studied for blood sugar control is now being investigated for conditions spanning cardiology, nephrology, hepatology, pulmonology, neurology, psychiatry, oncology, and reproductive medicine. If even a fraction of the emerging indications are confirmed in clinical trials, these peptide drugs could become the most widely prescribed medication class in history.
Questions still open
- Are the multi-organ benefits of GLP-1 RAs primarily direct drug effects or secondary consequences of weight loss and metabolic improvement?
- Which of the emerging indications (neurodegeneration, cancer, sepsis) are most likely to be confirmed in clinical trials?
- Will the four identified mechanisms translate into specific biomarkers that predict which patients will benefit most across different organ systems?
Common questions
How can one drug class treat so many different conditions?
Which new uses of GLP-1 drugs have the strongest evidence so far?
Read the original research
GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy.
Frontiers in pharmacology, 16, 1675552
Citation
Gong, Bing; Li, Couwen; Shi, Zhuang'e; Wang, FuPing; Dai, Ruanxian; Chen, Guobing; Su, Heng. (2025). GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy.. Frontiers in pharmacology, 16, 1675552. https://doi.org/10.3389/fphar.2025.1675552